E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Exposure to Varicella by children who have cancer. |
|
E.1.1.1 | Medical condition in easily understood language |
Exposure to chickenpox by children who have cancer. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10046980 |
E.1.2 | Term | Varicella |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this pilot trial is to establish the likely rate of patient recruitment in a projected full-scale Phase III trial and to gather data which will allow for an informed sample size calculation for the main trial.
This will enable a full-scale trial to compare the efficacy, safety and acceptability of varicella zoster immunoglobulin (VZIG) and aciclovir as post-exposure prophylaxis (PEP) for chickenpox in children receiving treatment for cancer. This would address the urgent need for evidence on how best to prevent chickenpox in children receiving treatment for cancer who are exposed to the virus. The proposed definitive study will be a multi-centre randomised controlled trial to compare aciclovir with VZIG. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the pilot study are • To create interest in and support for the study among paediatric oncologists • To identify the most important costs and health-related quality of life implications and define the data to be collected for the assessment of the cost-effectiveness in a subsequent Phase III trial. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For Registration: a) Under 16 years of age. b) EITHER diagnosed with cancer such that there is a standard expectation of immunocompromising therapy OR currently receiving immunocompromising treatment for cancer OR within 6 months (180 days) of having received immunocompromising treatment for cancer. c) No current or previous allogeneic or autologous haemopoietic stem cell transplantation / rescue. d) Negative VZV serostatus result at cancer diagnosis or negative VZV serostatus result within the last 3 months as assessed locally. e) Written informed consent to registration received from parent/legal representative and, where appropriate, written patient assent.
For randomisation: a) Patient has previously been registered in the PEPtalk2 trial, having satisfied all registration requirements. b) Registration criterion (c) continues to apply. c) Immunocompromising treatment for cancer must have been initiated prior to VZV exposure. d) Patient is able to commence either VZIG no more than 10 days after experiencing VZV exposure, or aciclovir at 7 days after experiencing VZV exposure (see sections 5.1.2 and 5.1.3). e) No renal impairment. Renal impairment is expressed in terms of glomerular filtration rate (ml/min/1.73m2). Child over 1 year: Estimated glomerular filtration rate (ml/min/1.73m2) = 40 x height (cm) x serum creatinine (micromol/litre). Normal renal function: > or equal to 90ml/min/1.73m2. f) Written informed consent to randomisation received from parent/legal representative and, where appropriate, written patient assent.
Important note regarding thrombocytopenia: platelets must be > 50 x 109/L to receive an intramuscular injection of VZIG. Therefore, if a child is randomised to receive VZIG and platelets are found to be < 50 x 109/L no more than 48 hours prior to VZIG administration, arrangements must be made by local staff to administer a platelet transfusion prior to VZIG injection. There are no criteria for platelet count if randomised to aciclovir. |
|
E.4 | Principal exclusion criteria |
Exclusion from Registration: a) 16 years of age or over. b) Current or previous allogeneic or autologous haemopoietic stem cell transplant/rescue. c) Positive VZV serostatus result as assessed locally within the last 3 months.
Note: renal impairment and thrombocytopenia are not absolute contraindications for registration as they might resolve by the time a chickenpox exposure and screening for randomisation occur.
Exclusion from randomisation: a) Positive VZV serostatus result at time of screening. b) Contraindication to either aciclovir or VZIG, including – (i) thrombocytopenia (platelets < 50 x 109/L) that has not been corrected by platelet transfusion; (ii) renal impairment (exclude any child with GFR below 90ml/min/1.73m2); (iii) any other contraindications deemed to be relevant by the local Investigator or the Sponsor’s Clinical Coordinator(s). c) Inability to start either VZIG within 10 days of VZV exposure, or aciclovir at 7 days after VZV exposure. d) More than one VZV exposure within the past 12 weeks. e) Inability to tolerate medications via oral or enteral route. f) Pregnancy or lactation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure will be the number of patients randomised within 12 months of the trial opening to recruitment. Considered in relation to the number of patients registered and the number of patients screened, this will allow an informed evaluation of the trial enrolment rate amongst eligible patients. Data will therefore be collected on patients screened for the study at each centre and the number of eligible patients at each centre who agree to registration and to randomisation.
In addition to the rate of enrolment, the following guidelines will also inform the design of the main study:
• compliance with allocated treatment; • adherence to study follow up; • acceptability of study procedures to patients and clinicians; • proportion of scheduled quality of life surveys completed; • proportion of patients for whom health care resource use and caregiver costs are collected.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The end of trial will be 5 months after last randomisation. This will allow sufficient time for the completion of protocol procedures, data collection and data input.
Trial data will then be analysed within 6 months of the LVLS. |
|
E.5.2 | Secondary end point(s) |
To gauge the acceptability of randomisation and intervention with either VZIG or aciclovir to proposed participants and their families and to estimate likely attrition rates To describe any symptomatic varicella occurring in trial participants within 12 (+/-2) weeks of either study intervention (VZIG or aciclovir) To describe details of the VZV exposure occurring in trial participants To assess varicella seroconversion at 12 (+/-2) weeks after PEP administration To provide data on which to estimate the required sample size for the full-scale trial To measure standardised health outcomes in trial participants who receive PEP and in those who develop varicella To collect information about costs and benefits of either study intervention to inform the assessment of cost-effectiveness in a subsequent Phase III trial To gauge acceptability of randomisation and intervention to paediatric oncologists To create interest in and support for the study among the study among relevant stakeholders including patients, families and healthcare teams |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The end of trial will be 5 months after last randomisation. This will allow sufficient time for the completion of protocol procedures, data collection and data input.
Trial data will then be analysed within 6 months of the LVLS. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial will be 5 months after last randomisation. This will allow sufficient time for the completion of protocol procedures, data collection and data input. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 23 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 23 |